Why is Capricor Therapeutics stock collapsing today? By Investing.com
Capricor Therapeutics’ stock fell about 58% in pre-open after the FDA advisory committee voted 9-3 against deramiocel for Duchenne muscular dystrophy cardiomyopathy, saying Phase 3 HOPE-3 lacked substantial effectiveness evidence. Analysts downgraded shares and cut targets, including Piper Sandler to Neutral from Overweight and $58 to $2. The FDA decision is due Aug. 22.
How this was made
The 30-second read
Why it matters
The advisory committee’s 9-3 vote against substantial effectiveness, plus analyst downgrades and removed price targets, shifts the market toward an FDA rejection scenario and reprices deramiocel’s probability of success.
Market read
Company-specific regulatory risk dominates today’s move, with the market pricing a likely second FDA rejection ahead of PDUFA.
What to watch
The article emphasizes the statistical-plan dispute; any subsequent FDA clarification or data re-interpretation could change the probability distribution into PDUFA.
Background
Deramiocel’s BLA was previously rejected in July 2025, and this is the second attempt at approval with a PDUFA date of August 22.
Ticker impact
Capricor Therapeutics shares plunged after an FDA advisory committee voted 9-3 against deramiocel’s Phase 3 HOPE-3 effectiveness evidence.
Further downside pressure likely into the PDUFA decision, with volatility elevated around any FDA/committee follow-ups.
The article cites a near-unanimous negative advisory vote, a second Complete Response Letter risk, and multiple same-day downgrades removing deramiocel value.
Market effects
Highlights heightened FDA scrutiny for gene and cell therapy efficacy evidence, potentially pressuring sentiment across similar late-stage programs.
Primarily US biotech-specific risk, with limited spillover given the article frames it as company-specific versus macro.
Could modestly affect global investor appetite for Duchenne cardiomyopathy and exosome/gene-therapy development risk.
Counterpoint
A negative advisory vote is not the final FDA decision; traders could fade the move if they expect the FDA to weigh the company’s finalized statistical plan differently than the committee.
Key entities
- companyCapricor Therapeutics
US-listed biotech whose deramiocel program faced a negative FDA advisory committee vote.
- regulatorFDA Cellular, Tissue, and Gene Therapies Advisory Committee
Advisory body that voted 9-3 against deramiocel’s Phase 3 HOPE-3 effectiveness evidence.
- productDeramiocel
Capricor’s lead therapy for cardiomyopathy in Duchenne muscular dystrophy, under FDA review.
- executiveLinda Marbán
CEO who disputed the FDA briefing materials’ statistical analysis plan during the committee meeting.
